DFTX
Definium Therapeutics, Inc.
Biotechnology · Healthcare · United States
36.33
close · 2026-10-30
value
97
cheaper than peers97
quality
24
stronger fundamentals24
ranked against
Biotechnology (pre-revenue)
value
quality
109 peerswide variation
Value inputs
| measure | company | vs peers |
| cash flow yield, 1 year ago | -1.6% | 95 |
| cash flow yield, 2 years ago | -1.3% | 95 |
| cash flow yield, 3 years ago | -1.0% | 94 |
| earnings yield, 3 years ago | -5.1% | 89 |
| cash flow yield, latest year | -2.7% | 88 |
| earnings yield, 1 year ago | -4.2% | 88 |
| earnings yield, latest year | -5.7% | 85 |
| earnings yield, 2 years ago | -6.7% | 80 |
| price to book | 5.31× | 27 |
9 of 12 measures available
Quality inputs
| measure | company | vs peers |
| operating margin | 0.0% | 50 |
| debt to equity | 14.6% | 35 |
| return on equity | -94.7% | 28 |
3 of 4 measures available
Facts
| market cap | $5B |
| free cash flow | -$45.6M |
| employees | 105 |
| first trade | 2016-11-15 |
| next earnings | 2026-11-09 |
| fundamentals updated | 2026-08-06 |
Annual history
| measure | 2025 | 2024 | 2023 | 2022 |
| diluted eps | -2.06 | -1.54 | -2.44 | -1.84 |
| free cash flow | -$131.6M | -$79.1M | -$64.4M | -$50.1M |
| net income | -$183.8M | -$108.7M | -$95.7M | -$56.8M |
| revenue | $0 | $0 | $0 | $0 |
| unusual items | -$23.0M | -$14.0M | -$6.5M | $8.0M |